The 45 most recent market catalysts affecting $BIIB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bullish
Impact 75
Biogen and Eisai Announce New Three-Year Real-World Findings for LEQEMBI
Biogen and Eisai released new three-year real-world data from their LEADER study for LEQEMBI, an Alzheimer's treatment. The key finding is a 76% lower rate of progression to modera…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 85
Biogen Announces Positive Two-Year Phase 2 Data for Diranersen in Early Alzheimer's Disease
Biogen announced compelling two-year Phase 2 data for diranersen, an antisense oligonucleotide therapy for early Alzheimer's disease. The drug demonstrated a 38% slowing of clinica…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 55
Biogen Canada Announces Private Payer Coverage for ZURZUVAE™
Biogen Canada announced that ZURZUVAE™ (zuranolone), its treatment for moderate or severe postpartum depression, has begun receiving reimbursement from numerous private group benef…
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Biogen at Buy, Raises Price Target to $270
HC Wainwright & Co. has maintained its 'Buy' rating on Biogen and raised its price target, signaling continued confidence in the biopharmaceutical company's prospects. This analyst…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Markets Raises Price Target on Biogen to $272
RBC Capital Markets has raised its price target on Biogen (BIIB) from $256 to $272, while reiterating an Outperform rating. This positive revision comes after the company's recent …
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Raises Biogen Price Target to $230
Barclays has raised its price target for Biogen from $200 to $230, a significant upgrade reflecting a more positive outlook on the company's valuation. This action is likely driven…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 85
Biogen Reports Q3 2026 Financial Results
Biogen announced Q3 2026 adjusted EPS of $2.62, significantly exceeding the FactSet consensus of $1.99, and revenue of $2.80 billion, also beating estimates. This strong performanc…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 65
Biogen Canada Announces Draft Recommendation for Expanded SPINRAZA Reimbursement
Biogen Canada has received a draft recommendation from Canada's Drug Agency (CDA) to expand public reimbursement for SPINRAZA, its spinal muscular atrophy (SMA) treatment. This is …
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 75
Biogen shares are trading higher after Wells Fargo maintained its Overweight rating on the stock and raised its price target from $250 to $310.
This headline indicates a significant positive catalyst for Biogen. An analyst upgrade from a major financial institution like Wells Fargo, coupled with a substantial price target …
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310
Wells Fargo analyst Mohit Bansal maintained an 'Overweight' rating on Biogen (BIIB) and raised the price target from $250 to $310. This action signals increased confidence from a p…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 55
Biogen To Demonstrate Data, Additional Scientific Presentations From Its Nephrology Portfolio At American Society Of Nephrology Kidney Week
Biogen is announcing its participation and planned presentations at the American Society of Nephrology Kidney Week in October 2026. This event is significant for the company as it …
Oct 14, 2026
Corporate Catalyst
Neutral
Impact 65
FDA Launches The Rare Disease Framework Initiative To Develop A Holistic, Fit-For-Purpose Framework For Rare Disease Drug Development
The FDA has launched its Rare Disease Framework Initiative, a significant move to develop a more streamlined and effective regulatory pathway for rare disease drug development. Thi…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 75
Biogen shares are trading higher after JP Morgan upgraded its rating on the stock from Neutral to Overweight and raised its price target from $210 to $300.
This headline represents a significant corporate catalyst for Biogen. An upgrade from a major investment bank like JP Morgan, coupled with a substantial increase in the price targe…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300
JP Morgan analyst Chris Schott upgraded Biogen (BIIB) from Neutral to Overweight and raised its price target from $210 to $300. This move indicates a more optimistic outlook from a…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 75
Biogen shares are trading higher after UBS maintained its Buy rating and raised its price target on the stock from $240 to $270.
The UBS upgrade and price target increase for Biogen (BIIB) is a significant positive catalyst for the stock, indicating strong analyst conviction. This move suggests that UBS sees…
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Biogen, Raises Price Target to $270
UBS analyst Michael Yee has raised the price target for Biogen (BIIB) from $240 to $270 while maintaining a 'Buy' rating. This action signals increased confidence from a prominent …
Oct 8, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $256
RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating for Biogen, signaling continued confidence in the company's long-term prospects. However, the price target wa…
Oct 2, 2026
Corporate Catalyst
Bullish
Impact 65
Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated
Biogen announced 52-week results from the Phase 2 part of its AMETHYST trial for litifilimab in cutaneous lupus erythematosus (CLE). The data showed continued clinical improvements…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 65
Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75% Proteinuria Reduction For EMPAVELI In Rare Kidney Diseases
Biogen has announced the publication of detailed adolescent subgroup data from its Phase 3 VALIANT study for EMPAVELI, showing a 75% reduction in proteinuria and stabilization of k…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Piper Sandler analyst David Amsellem reaffirmed his 'Overweight' rating on Biogen and raised the price target from $225 to $245. This action signals continued confidence in Biogen'…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 65
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Biogen and Eisai received approval from China's NMPA for the subcutaneous, at-home weekly formulation of Leqembi, their Alzheimer's treatment. This is significant because it provid…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Biogen, Raises Price Target to $260
RBC Capital's analyst Brian Abrahams has maintained an 'Outperform' rating for Biogen and raised the price target from $240 to $260. This action signals continued confidence in Bio…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
Eisai And Biogen Announce Once Weekly Lecanemab-Irmb Subcutaneous Injection Is Now Available In U.S. For Initiation Therapy For Early Alzheimer’s Disease
Eisai and Biogen have made their Alzheimer's drug, LEQEMBI IQLIK, available in a once-weekly subcutaneous injection format in the U.S. This is significant because it provides a mor…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target
Wolfe Research analyst Alexandria Hammond upgraded Biogen (BIIB) from 'Peer Perform' to 'Outperform' and announced a new price target of $300. This upgrade indicates a more bullish…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Biogen, Raises Price Target to $241
Mizuho analyst Salim Syed maintaining an 'Outperform' rating and raising the price target for Biogen (BIIB) from $221 to $241 signals continued confidence in the company's prospect…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Biogen, Raises Price Target to $240
UBS analyst Michael Yee maintained a 'Buy' rating on Biogen and raised the price target from $225 to $240. This action signals a positive outlook from a prominent financial institu…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251
HC Wainwright & Co. analyst Andrew S. Fein has maintained a 'Buy' rating on Biogen and raised the price target from $237 to $251. This action signals continued confidence in Biogen…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231
Morgan Stanley analyst Matthew Harrison has reiterated an 'Equal-Weight' rating on Biogen, but has raised the price target from $222 to $231. This adjustment reflects a slightly im…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240
RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating on Biogen, signaling continued confidence in the company's long-term prospects. However, the price target was…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248
Canaccord Genuity's analyst Sumant Kulkarni reaffirmed a 'Buy' rating for Biogen and a slight increase in the price target from $245 to $248. This action signals continued confiden…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Biogen, Raises Price Target to $225
TD Cowen analyst Phil Nadeau maintained a 'Buy' rating on Biogen and raised the price target from $215 to $225. This action signals continued confidence in Biogen's future performa…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen's Q2 earnings and revenue significantly surpassed consensus estimates, driven by strong sales of key drugs like Spinraza, Leqembi, Skyclarys, and Zurzuvae, alongside contrib…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Biogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance above estimates. Also, Barclays raised its price target on the stock from $185 to $200.
This headline is a major corporate catalyst for Biogen. The combination of strong financial performance, upward revised guidance, and an analyst price target increase creates a pow…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Biogen Lowers FY2026 Adj EPS Guidance from $14.25-$15.25 to $12.00-$13.00 vs $12.83 Est
Biogen (BIIB) has announced a substantial reduction in its adjusted EPS guidance for fiscal year 2026. The new range of $12.00-$13.00 is a significant decrease from the previous $1…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
CORRECTION: Biogen Raises FY2026 Adj EPS Guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 Est
Biogen (BIIB) has announced a significant upward revision to its adjusted EPS guidance for fiscal year 2026, moving from a range of $15.25-$16.25 to $15.85-$16.85. This new forecas…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Biogen Q2 Adj. EPS $3.60 Beats $2.96 Estimate, Sales $2.736B Beat $2.458B Estimate
Biogen's significant beat on both top and bottom lines is a strong positive catalyst for the company, indicating better-than-expected performance, potentially from strong sales of …
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Biogen, Raises Price Target to $280
Guggenheim analyst Brad Canino has raised the price target for Biogen (BIIB) from $260 to $280 while maintaining a 'Buy' rating. This upgrade signals increased confidence from a pr…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 85
Why Is Biogen Stock Falling Tuesday?
Biogen's stock fell nearly 9% after presenting new Phase 2 data for its investigational Alzheimer's therapy, diranersen. While the data showed the drug slowed clinical decline and …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 75
Eisai And Biogen Present Real‑World LEADER Study Data At AAIC Showing Nearly 83% Of Early Alzheimer’s Patients Remained Stable Or Improved On LEQEMBI Therapy Over ~17 Months, With Consistent Results Across Diverse Groups.
Eisai and Biogen presented real-world data from the LEADER study for their Alzheimer's drug LEQEMBI, indicating that nearly 83% of early Alzheimer's patients remained stable or imp…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 85
Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of Boxes
Biogen announced compelling Phase 2 results for diranersen, an investigational Alzheimer's drug, showing consistent efficacy across various measures of cognition and daily function…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 75
Biogen shares are trading higher after Truist Securities upgraded the stock from Hold to Buy rating and raised its price target from $190 to $235.
This headline indicates a strong positive sentiment shift for Biogen (BIIB) following a significant upgrade from a reputable financial institution. The move from 'Hold' to 'Buy' an…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 65
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
The filing reports multiple analyst upgrades for five distinct companies: Nio, Capital One, Keysight, Biogen, and American Express. These upgrades, moving from 'Neutral'/'Hold'/'Eq…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Truist Securities Upgrades Biogen to Buy, Raises Price Target to $235
Truist Securities analyst Srikripa Devarakonda upgraded Biogen (BIIB) from a 'Hold' to a 'Buy' rating and raised the price target from $190 to $235. This analyst action signals inc…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.